아시아 태평양 림프부종 치료 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 림프부종 치료 시장 – 2029년까지의 산업 동향 및 예측

  • Healthcare
  • Published Report
  • Dec 2021
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 195
  • 그림 수: 48

아시아 태평양 림프부종 치료 시장, 치료 유형(압박 요법, 수술, 약물 요법, 레이저 요법 및 기타), 유형(1차 림프부종 및 2차 림프부종), 영향을 받는 부위(생식기, 하지, 상지 및 기타), 연령대(성인 및 노인), 투여 경로(경구, 주사 및 기타), 최종 사용자(병원, 외래 수술 센터, 전문 클리닉 및 기타), 유통 채널(직접 입찰, 약국 매장 및 기타), 국가(일본, 중국, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남 및 아시아 태평양의 나머지 지역) 산업 동향 및 2029년까지의 예측

아시아 태평양 림프부종 치료 시장시장 분석 및 통찰력: 아시아 태평양 림프부종 치료 시장

아시아 태평양 림프부종 치료 시장은 2022년부터 2029년까지의 예측 기간 동안 상당한 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 아시아 태평양 림프부종 치료 시장이 2022년부터 2029년까지의 예측 기간 동안 11.4%의 CAGR로 성장하고 있으며 2022년 1억 269만 달러에서 2029년까지 2억 3,913만 달러에 도달할 것으로 예상한다고 분석했습니다. 증가하는 의료비 지출과 혁신 및 기술의 확대는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.

림프부종은 일반적으로 상지와 하지에 발생하는 부기를 말합니다. 때로는 두 팔과 두 다리가 부기도 합니다. 림프부종은 암 치료의 일환으로 림프절을 제거하거나 손상시켜 가장 흔히 발생합니다. 면역 체계의 일부인 림프계가 막혀 발생합니다. 손상된 림프계에서 비롯되며 감염 , 변형, 쇠약해지는 통증 및 장애로 이어질 수 있습니다. 림프부종을 치료할 수 있는 방법은 없습니다.

림프부종 치료는 표준 치료 대신 여러 가지 요법을 포함합니다. 환자들이 림프부종의 기존 치료에 불만족하거나 치료되지 않기 때문입니다. 그들은 건강 관리 결정에 대한 통제력을 더 많이 제공하는 대체 치료법에 접근하며 , 대안은 환자의 건강 시스템과 더 호환되는 것으로 밝혀졌습니다.

림프부종은 림프절 배수에 영향을 미치는 암이나 치료 후에 발생할 수 있습니다. 유방암 치료 후 며칠에서 최대 30년 후에 발생하는 것으로 보고되었습니다. 초기 단계 림프부종 치료법에는 요법 , 수술 및 림프정맥 이식 등이 있습니다. 그러나 림프부종을 영구적으로 치료할 수 있는 방법은 없습니다.

A growing number of people are affected with lymphedema which demand highly effective and advanced treatment to minimize the risk during the treatment. The healthcare systems need highly advanced therapies for numerous lymphedema disorders during the treatment of patients. Therefore, the major market players are highly focusing on product launches and product approvals. Additionally, the government and regulatory bodies are supporting market players by virtue of product approval.

The demand for lymphedema treatment has rapidly increased all over the world during the past decade due to the increased incidence of lymphedema patients.

High cost of treatment and adverse side-effects associated with treatment are anticipated to hinder market growth in the projected period.

Strategic initiatives by the market players, increasing healthcare expenditure, soaring number of drugs manufacturers act as an opportunity for this market and is expected to impel the market growth.

It is expected that no permanent cure for lymphedema is the major key challenge for the future growth of Asia-Pacific lymphedema treatment market.

Asia-Pacific lymphedema treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.  

아시아 태평양 림프부종 치료 시장Asia-Pacific Lymphedema Treatment Market and Market Size

Asia-Pacific lymphedema treatment market is segmented on the basis of treatment type, by type, by affected area, by age group, by route of administration, by end user, by distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of treatment type, Asia-Pacific lymphedema treatment market is segmented in compression therapy, surgery, drug therapy, laser therapy and others.  In 2022, compression therapy segment is expected to dominate the market due to public-private collaborations in drug and medical devices development.
  • On the basis of type, Asia-Pacific lymphedema treatment market is segmented in primary lymphedema and secondary lymphedema.  In 2022, secondary lymphedema segment is expected to dominate the market due to rise in number of lymphedema patients globally.
  • On the basis of affected area, Asia-Pacific lymphedema treatment market is segmented genital, lower extremity and upper extremity. In 2022, lower extremity segment is expected to dominate the market due to rise in number of therapies conducted for the treatment of lymphedema.
  • 연령대를 기준으로 아시아 태평양 림프부종 치료 시장은 성인과 노인으로 세분화됩니다. 2022년에는 성인 인구에서 림프부종의 유병률이 증가함에 따라 성인 세그먼트가 시장을 지배할 것으로 예상됩니다.
  • 투여 경로를 기준으로 아시아 태평양 림프부종 치료 시장은 경구, 주사 및 기타로 세분화됩니다. 2022년에는 경구 세그먼트가 연구 개발 증가로 시장을 지배할 것으로 예상됩니다. 질병의 유병률이 높아 림프부종 치료에 대한 수요가 증가하고 연구 개발이 급증할 것이기 때문입니다.
  • 최종 사용자를 기준으로, 아시아 태평양 림프부종 치료 시장은 병원, 외래 수술 센터, 전문 클리닉 등으로 세분화됩니다. 2022년에는 주요 시장 참여자들의 제품 출시가 증가함에 따라 병원 부문이 시장을 지배할 것으로 예상됩니다.
  • 유통 채널을 기준으로 아시아 태평양 림프부종 치료 시장은 직접 입찰, 약국 매장 및 기타로 세분화됩니다. 2022년에는 정부의 약물 승인 증가로 인해 약국 매장 부문이 시장을 지배할 것으로 예상됩니다.

아시아 태평양 림프부종 치료 시장 국가 수준 분석

아시아 태평양 림프부종 치료 시장을 치료 유형별, 유형별, 영향을 받는 지역별, 연령대별, 투여 경로별, 최종 사용자별, 유통 채널별로 분석하고 시장 규모 정보를 제공합니다.

아시아 태평양 림프부종 치료 시장 보고서에서 다루는 국가는 중국, 아르헨티나, 페루, 남미 지역입니다.

아시아 태평양 지역 정부의 자금 지원이 점차 늘어나면서 중국이 이 지역의 림프부종 치료 시장을 장악할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

아시아 태평양 림프부종 치료 시장에서 증가하는 의료비 지출과 혁신 및 기술의 확대는 아시아 태평양 림프부종 치료 시장 참여자들에게 새로운 기회를 창출하고 있습니다.

중국 내 아시아 태평양 림프부종 치료 시장 지역 세그먼트는 가장 높은 성장률을 보일 것으로 예상되며, 정부 자금 지원 증가로 인해 2022년부터 2029년까지 예측 기간 동안 해당 지역을 지배할 것입니다.

아시아 태평양 림프부종 치료 시장은 아시아 태평양 림프부종 치료 시장 판매와 관련하여 특정 산업의 모든 국가별 성장, 아시아 태평양 림프부종 치료 시장 발전의 영향, 아시아 태평양 림프부종 치료 시장에 대한 지원과 관련된 규제 시나리오의 변화에 ​​대한 자세한 시장 분석을 제공합니다. 

경쟁 환경 및 아시아 태평양 림프부종 치료 시장 점유율 분석

아시아 태평양 림프부종 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세 및 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 아시아 태평양 림프부종 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

보고서에서 다루는 주요 기업은 Bio Compression Systems, Inc., Lohmann & Rauscher, Mego Afek ltd, SIGVARIS, Tactile Systems Technology Inc., medi GmbH & Co. KG, Paul Hartmann AG, Sanyleg Srl, 3M, ConvaTec Inc., Julius Zorn GmbH, Cardinal Health, Inc., Smith & Nephew plc, ThermoTek, Huntleigh Healthcare Limited, Herantis Pharma Plc입니다. 이들은 아시아 태평양 림프부종 치료 시장 참여자입니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 별도로 제공합니다.

또한 전 세계 여러 회사에서 다양한 제품 출시와 계약을 체결하여 아시아 태평양 림프부종 치료 시장을 더욱 가속화하고 있습니다.

예를 들어,

  • 2021년 6월, InfuSystem Holdings, Inc.는 Bio Compression Systems, Inc.와 공동 계약을 체결했다고 발표했습니다. 이 계약에 따라 InfuSystem은 자사의 Integrated Therapy Service("ITS") 플랫폼 시설에 림프부종 치료를 추가할 예정입니다. 이를 통해 두 회사의 매출이 증가하여 수익 창출에 도움이 되었습니다.
  • 2020년 4월, L&R 그룹은 압박 시장에서 입지를 강화했습니다. L&R은 프랑스 압박 전문가 MTA의 자산을 인수했습니다. 이 인수를 통해 L&R은 정맥 부전 및 림프부종 치료에 대한 제품 포트폴리오를 확장하여 프랑스에서 시장 입지를 강화했습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL'S ANALYSIS

4.2 PORTER'S MODEL

5 PIPELINE ANALYSIS FOR ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET

6 EPIDEMIOLOGY

7 REGULATORY GUIDELINES FOR ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET

7.1 U.S.

7.2 EUROPE

7.3 INDIA

7.4 MEXICO

7.5 CANADA

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES ASIA PACIFICLY

8.1.2 INCREASE IN THE PREVALENCE OF CANCERS

8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES

8.1.4 MULTIPLE THERAPIES

8.2 RESTRAINTS

8.2.1 HIGH COST OF TREATMENT

8.2.2 LACK OF AWARENESS ABOUT THE DISEASE

8.3 OPPORTUNITIES

8.3.1 DRUG APPROVALS

8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS

8.4 CHALLENGES

8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA

8.4.2 DIFFICULT REIMBURSEMENT

9 IMPACT OF COVID-19 ON THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET

9.1 IMPACT ON PRICE

9.2 IMPACT ON DEMAND

9.3 IMPACT ON SUPPLY CHAIN

9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS

9.5 CONCLUSION

10 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE

10.1 OVERVIEW

10.2 COMPRESSION THERAPY

10.2.1 BY PRODUCT

10.2.1.1 COMPRESSION PUMPS

10.2.1.2 COMPRESSION GARMENTS

10.2.1.2.1 COMPRESSION STOCKINGS

10.2.1.2.2 COMPRESSION SLEEVES

10.2.1.2.3 OTHERS

10.2.1.3 COMPRESSION BANDAGES & WRAPS

10.2.1.4 OTHERS

10.2.2 BY TECHNIQUE

10.2.2.1 STATIC COMPRESSION THERAPY

10.2.2.2 DYNAMIC COMPRESSION THERAPY

10.3 SURGERY

10.3.1 LYMPHOVENOUS TRANSPLANT

10.3.2 LYMPHATICOVENOUS ANASTOMOSIS

10.3.3 LIPOSUCTION

10.3.4 OTHERS

10.4 DRUG THERAPY

10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

10.4.2 RETINOIDS

10.4.3 ANTIBIOTICS

10.4.4 OTHERS

10.5 LASER THERAPY

10.6 OTHERS

11 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE

11.1 OVERVIEW

11.2 SECONDARY LYMPHEDEMA

11.3 PRIMARY LYMPHEDEMA

11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE)

11.3.2 CONGENITAL LYMPHEDEMA

11.3.3 LYMPHEDEMA TARDA

12 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA

12.1 OVERVIEW

12.2 LOWER EXTREMITY

12.3 UPPER EXTREMITY

12.4 GENITALIA

13 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP

13.1 OVERVIEW

13.2 ADULT

13.3 GERIATRIC

13.4 PEDIATRIC

14 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.3 INJECTABLE

14.4 TOPICAL

15 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITAL

15.3 SPECIALTY CLINICS

15.4 AMBULATORY SURGICAL CENTERS

15.5 OTHERS

16 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 PHARMACY STORES

16.3 DIRECT TENDER

16.4 OTHERS

17 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY REGION

17.1 ASIA-PACIFIC

17.1.1 CHINA

17.1.2 JAPAN

17.1.3 INDIA

17.1.4 SOUTH KOREA

17.1.5 AUSTRALIA

17.1.6 INDONESIA

17.1.7 SINGAPORE

17.1.8 PHILIPPINES

17.1.9 THAILAND

17.1.10 MALAYSIA

17.1.11 VIETNAM

17.1.12 REST OF ASIA-PACIFIC

18 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

19 SWOT ANALYIS

20 COMPANY PROFILE

20.1 TACTILE MEDICAL

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENT

20.1.6 CLINICAL TRIAL:

20.2 ESSITY (BSN MEDICAL GMBH)

20.2.1 COMPANY SNAPSHOT

20.2.2 COMPANY SHARE ANALYSIS

20.2.3 PRODUCT PORTFOLIO

20.2.4 RECENT DEVELOPMENT

20.3 3M

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENTS

20.3.6 NEW BUSINESS SEGMENT

20.3.7 ACQUISITION

20.4 CARDINAL HEALTH

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENT

20.5 LOHMANN & RAUSCHER GMBH & CO. KG

20.5.1 COMPANY SNAPSHOT

20.5.2 COMPANY SHARE ANALYSIS

20.5.3 PRODUCT PORTFOLIO

20.5.4 RECENT DEVELOPMENT

20.6 AIROS MEDICAL, INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.6.4 PRODUCT LAUNCH:

20.7 AVET PHARMACEUTICALS INC.

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 BIOCOMPRESSION SYSTEMS

20.8.1 COMPANY SNAPSHOT

20.8.2 PRODUCT PORTFOLIO

20.8.3 RECENT DEVELOPMENT

20.8.4 AGREEMENT

20.9 CONVATEC INC.

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENT

20.1 HERANTIS PHARMA PLC

20.10.1 COMPANY SNAPSHOT

20.10.2 RECENT DEVELOPMENT

20.11 HUNTLEIGH HEALTHCARE LIMITED

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENT

20.12 JUZO

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 KOYA MEDICAL

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.13.4 APPROVAL

20.14 MEDI GMBH & CO. KG

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.15 MEGO AFEK LTD

20.15.1 COMPANY SNAPSHOT

20.15.2 PRODUCT PORTFOLIO

20.15.3 RECENT DEVELOPMENT

20.15.4 APPLICATION LAUNCH:

20.16 PAUL HARTMANN AG

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENTS

20.17 SANYLEG SRL A SOCIO UNICO

20.17.1 COMPANY SNAPSHOT

20.17.2 PRODUCT PORTFOLIO

20.17.3 RECENT DEVELOPMENT

20.18 SIGVARIS GROUP

20.18.1 COMPANY SNAPSHOT

20.18.2 PRODUCT PORTFOLIO

20.18.3 RECENT DEVELOPMENTS

20.18.4 PRODUCT LAUNCHES:

20.19 SMITH +NEPHEW

20.19.1 COMPANY SNAPSHOT

20.19.2 REVENUE ANALYSIS

20.19.3 PRODUCT PORTFOLIO

20.19.4 RECENT DEVELOPMENT

20.2 THERMOTEK

20.20.1 COMPANY SNAPSHOT

20.20.2 PRODUCT PORTFOLIO

20.20.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

표 목록

TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT:

TABLE 2 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 ASIA PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 35 ASIA PACIFIC PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 ASIA PACIFIC DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 ASIA PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 39 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 40 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 41 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 42 ASIA-PACIFIC COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 43 ASIA-PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 44 ASIA-PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 45 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 46 ASIA-PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 48 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 49 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 50 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 51 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 52 CHINA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 53 CHINA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 54 CHINA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 55 CHINA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 56 CHINA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 57 CHINA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 58 CHINA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 CHINA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 CHINA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 61 CHINA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 62 CHINA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 63 CHINA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 CHINA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 JAPAN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 66 JAPAN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 67 JAPAN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 68 JAPAN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 69 JAPAN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 70 JAPAN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 71 JAPAN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 JAPAN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 JAPAN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 74 JAPAN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 75 JAPAN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 76 JAPAN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 77 JAPAN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 INDIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 79 INDIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 80 INDIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 81 INDIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 82 INDIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 83 INDIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 84 INDIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 85 INDIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 INDIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 87 INDIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 88 INDIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 89 INDIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 90 INDIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 91 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 92 SOUTH KOREA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 93 SOUTH KOREA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 94 SOUTH KOREA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 95 SOUTH KOREA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 96 SOUTH KOREA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 97 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 SOUTH KOREA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 99 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 100 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 101 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 102 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 103 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 104 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 105 AUSTRALIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 106 AUSTRALIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 107 AUSTRALIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 108 AUSTRALIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 109 AUSTRALIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 110 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 111 AUSTRALIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 112 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 113 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 114 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 115 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 116 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 117 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 118 INDONESIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 119 INDONESIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 120 INDONESIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 121 INDONESIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 122 INDONESIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 123 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 INDONESIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 125 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 126 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 127 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 128 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 129 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 130 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 131 SINGAPORE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 132 SINGAPORE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 133 SINGAPORE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 134 SINGAPORE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 135 SINGAPORE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 136 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 137 SINGAPORE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 138 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 139 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 140 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 141 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 142 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 143 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 144 PHILIPPINES COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 145 PHILIPPINES COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 146 PHILIPPINES COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 147 PHILIPPINES SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 148 PHILIPPINES DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 149 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 150 PHILIPPINES PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 152 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 153 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 154 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 155 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 156 THAILAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 157 THAILAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 158 THAILAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 159 THAILAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 160 THAILAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 161 THAILAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 162 THAILAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 163 THAILAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 164 THAILAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 165 THAILAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 166 THAILAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 167 THAILAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 168 THAILAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 169 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 170 MALAYSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 171 MALAYSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 172 MALAYSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 173 MALAYSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 174 MALAYSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 175 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 MALAYSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 177 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 178 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 179 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 180 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 181 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 182 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 183 VIETNAM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 184 VIETNAM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)

TABLE 185 VIETNAM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 186 VIETNAM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 187 VIETNAM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 188 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 189 VIETNAM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 190 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)

TABLE 191 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)

TABLE 192 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 193 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 194 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 195 REST OF ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : SEGMENTATION

FIGURE 2 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : DROC ANALYSIS

FIGURE 4 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: ASIA PACIFIC VS REGIONAL ANALYSIS

FIGURE 5 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : MARKET APPLICATION COVERAGE GRID

FIGURE 9 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET AND ASIA-PACIFIC TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET

FIGURE 15 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2021

FIGURE 16 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2020-2029 (USD MILLION)

FIGURE 17 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 18 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 19 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2021

FIGURE 20 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)

FIGURE 21 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 22 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2021

FIGURE 24 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2020-2029 (USD MILLION)

FIGURE 25 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2022-2029)

FIGURE 26 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE

FIGURE 27 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2021

FIGURE 28 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)

FIGURE 29 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2022-2029)

FIGURE 30 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 31 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 32 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

FIGURE 33 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 34 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, 2021

FIGURE 36 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 37 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 38 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 40 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 41 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL ,CAGR (2022-2029)

FIGURE 42 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 44 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 45 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 46 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 47 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE (2022-2029)

FIGURE 48 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.